Drug recall
Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc…
FDA recall event 91717 · Class III · Sciegen Pharmaceuticals Inc
Key facts
| Event ID | 91717 |
|---|---|
| Recall numbers | D-0354-2023 |
| Recalling firm | Sciegen Pharmaceuticals Inc |
| Product type | Drugs |
| Products | Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05. |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm Initiated |
| Reason for recall | Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles. |
| Initiation date | Feb 17, 2023 |
| Report date | Mar 8, 2023 |
| Termination date | Jun 17, 2024 |
| City | Hauppauge |
| State | NY |
| Country | United States |
| FEI number | 3008298016 |
At a glance
- 1–9 Products in this recall
- 10–99 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports · Source date: